Emrelis: Dosage Form, Projected Sales, NCE-1 Date | Telisotuzumab Vedotin-Tllv

Emrelis

Emrelis is an antibody‑drug conjugate for adults with locally advanced or metastatic non-squamous non-small cell lung cancer overexpressing c‑Met after prior therapy. It delivers targeted chemotherapy directly to cancer cells to inhibit tumor progression.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Telisotuzumab Vedotin-Tllv
Innovator :

ABBVIE INC
Approval Date :

14-May-25
Data Exclusivity Expiry :

14-May-29
Market Exclusivity Expiry :

14-May-37
Dosage Form :

Single-Dose Vial
Strength :

20MG and 100MG
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

23
2026 :

99
2027 :

232
2028 :

418
2029 :

576
2030 :

724
2031 :

876

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Emrelis

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?